1. Survival After Surgical Resection of Stage IV Esophageal Cancer
Sahar A. Saddoughi, MD, PhD, J. Matthew Reinersman, MD, Yuriy O. Zhukov, MD, James Taswell, PA-C, Kristin Mara, MS, S. William Harmsen, MS, Shanda H. Blackmon, MD, MPH, Stephen D. Cassivi, MD, Francis Nichols, MD, K. Robert Shen, MD, Dennis A. Wigle, MD, PhD, Mark S. Allen, MD 
The Annals of Thoracic Surgery 
Volume 103, Issue 1, Pages (January 2017)
DOI: /j.athoracsur
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Median overall survival (OS) is 331 days, and 1-year OS is 29%, 2-year OS is 17.8%, and 5-year OS is 6%. (Post-Op = postoperatively.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Overall survival is not significantly different between patients where M1 disease was known preoperatively or postoperatively (p = ) However, the trend suggests that preoperative diagnosis of M1 disease where patients have been treated with neoadjuvant chemoradiation may be associated with increased survival from stage IV esophageal cancer. (M1 = metastasis; Post-op = postoperatively; Pre-op = preoperatively.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Low T stage has significant survival advantage. Patients with T1/T2 tumors had a median survival of 846 days, while patients with T3/T4 tumors had a median survival of 226 days (p = ). (Post-Op = postoperatively.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

5. Fig 4
Neoadjuvant therapy has a significant survival advantage for patients with Stage IV esophageal cancer (p = 0.03). (Post-op = postoperatively; Tx = treatment.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions